Delivra Health Brands Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Delivra Health Brands has been growing earnings at an average annual rate of 53.3%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been growing at an average rate of 15.8% per year. Delivra Health Brands's return on equity is 16.9%, and it has net margins of 7.1%.
Belangrijke informatie
53.3%
Groei van de winst
56.2%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 23.1% |
| Inkomstengroei | 15.8% |
| Rendement op eigen vermogen | 16.9% |
| Nettomarge | 7.1% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Delivra Health Brands geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 12 | 1 | 6 | 0 |
| 31 Mar 24 | 12 | -1 | 5 | 0 |
| 31 Dec 23 | 11 | -1 | 5 | 0 |
| 30 Sep 23 | 12 | 0 | 5 | 0 |
| 30 Jun 23 | 10 | 0 | 5 | 0 |
| 31 Mar 23 | 8 | -2 | 5 | 0 |
| 31 Dec 22 | 8 | -3 | 5 | 0 |
| 30 Sep 22 | 8 | -6 | 6 | 0 |
| 30 Jun 22 | 8 | -7 | 6 | 0 |
| 31 Mar 22 | 8 | -12 | 8 | 0 |
| 31 Dec 21 | 8 | -12 | 8 | 0 |
| 30 Sep 21 | 8 | -21 | 8 | 0 |
| 30 Jun 21 | 8 | -23 | 9 | 0 |
| 31 Mar 21 | 8 | -24 | 8 | 0 |
| 31 Dec 20 | 8 | -54 | 11 | 0 |
| 30 Sep 20 | 8 | -55 | 11 | 0 |
| 30 Jun 20 | 8 | -57 | 14 | 0 |
| 31 Mar 20 | 3 | -60 | 17 | 0 |
| 31 Dec 19 | 4 | -34 | 19 | 0 |
| 30 Sep 19 | 6 | -26 | 20 | 0 |
| 30 Jun 19 | 6 | -26 | 20 | 0 |
| 31 Mar 19 | 9 | -19 | 17 | 0 |
| 31 Dec 18 | 6 | -17 | 15 | 0 |
| 30 Sep 18 | 2 | -17 | 13 | 0 |
| 30 Jun 18 | 1 | -13 | 10 | 0 |
| 31 Mar 18 | 0 | -13 | 9 | 0 |
| 31 Dec 17 | 0 | -12 | 8 | 0 |
| 30 Sep 17 | 0 | -10 | 6 | 0 |
| 30 Jun 17 | 0 | -8 | 5 | 0 |
| 31 Mar 17 | 0 | -4 | 3 | 0 |
| 31 Dec 16 | 0 | -3 | 2 | 0 |
| 30 Sep 16 | 0 | -3 | 2 | 0 |
| 30 Jun 16 | 0 | -3 | 2 | 0 |
Kwaliteitswinsten: DHB has a large one-off gain of CA$1.8M impacting its last 12 months of financial results to 30th June, 2024.
Groeiende winstmarge: DHB became profitable in the past.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: DHB has become profitable over the past 5 years, growing earnings by 53.3% per year.
Versnelling van de groei: DHB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Winst versus industrie: DHB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Rendement op eigen vermogen
Hoge ROE: DHB's Return on Equity (16.9%) is considered low.